Key Highlights

  • INNV shares are up 9.41% premarket to $11.51, building on Tuesday's regular-session close of $10.52.
  • Full-year 2026 Revenue grew 15.9% to $989.7 million, with adjusted EBITDA jumping to $94.6 million, a 9.6% margin, from $34.5 million a year earlier.
  • Net loss narrowed sharply to $0.7 million from $35.3 million, while adjusted EPS of $0.06 missed estimates by a penny.
  • Fiscal 2027 guidance calls for revenue of $1.05 billion-$1.085 billion and adjusted EBITDA of $105 million-$115 million.
  • Management's 'InnovAge 3.0' strategy emphasizes AI-driven care tools, census growth, and potential de novo market expansion.

Margin Expansion Highlights Fiscal Fourth-Quarter Results

InnovAge Holding (NASDAQ:INNV) shares are trading sharply higher premarket after the PACE healthcare provider reported fiscal fourth-quarter and full-year 2026 results showing dramatic Margin expansion and issued strong fiscal 2027 guidance. Full-year revenue grew 15.9% to $989.7 million, while adjusted EBITDA jumped approximately 175% to $94.6 million, a 9.6% margin, from $34.5 million a year earlier, and net loss narrowed sharply to $0.7 million from a $35.3 million loss in fiscal 2025, impacted by one-time legal accruals.

InnovAge Holding, headquartered in Denver, Colorado, is the largest scaled multi-state provider of the Program of All-Inclusive Care for the Elderly, known as PACE, serving approximately 7,700-8,000 high-cost, frail, and predominantly dual-eligible seniors across 20 centers in California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia. The company operates a capitated, risk-bearing care model, receiving fixed monthly payments from Medicare and Medicaid to deliver comprehensive medical, social, and long-term care services, including in-home care, primary care, therapy, dental, mental health, transportation, and meals.

Fiscal 2027 Guidance Points to Continued Growth

Fiscal 2027 guidance calls for an ending census of approximately 8,625 to 8,850 participants, member months of 101,000 to 102,500, total revenue of $1.05 billion to $1.085 billion, and adjusted EBITDA of $105 million to $115 million, with de novo losses of $0.4 million to $0.8 million, primarily related to a newer market. Medicare rate increases are expected at 1.5%-2.0% net, reflecting a roughly even blend of risk models starting in January.

'InnovAge 3.0' Strategy Emphasizes Technology and Disciplined Growth

The company describes entering an 'InnovAge 3.0' phase focused on scaling capabilities, including investments in participant experience, technology and data infrastructure, and AI initiatives, including an AI-enabled consultation agent for frailty and geriatric care and a medication optimization agent, both scaling organization-wide. Leadership was strengthened with a new president and chief operating officer joining from an external healthcare background, and management emphasized Capital allocation priorities that favor filling existing center capacity and pursuing disciplined acquisitions over de novo expansion.

Policy Engagement and Rate-Setting Remain Key Watch Items

Ongoing policy engagement includes efforts to reduce barriers to existing PACE program growth and exploratory discussions about applying PACE model attributes to adjacent populations, while California and Colorado rate-setting processes representing roughly 70% of the company's census remain unresolved, a Factor investors will watch closely in the coming quarters.